预测急性移植物抗宿主病严重程度的生物标志物前瞻性外部验证
这项前瞻性非干预研究纳入204例急性GVHD患者,在GVHD发病时检测7种血浆生物标志物(Elafin、HGF、IL2RA、IL8、REG3、ST2、TNFRI),用Ann Arbor/MAGIC联盟算法预测D28激素完全反应、D180总生存和D180非复发死亡。初始GVHD分级和胆红素与所有结局显著相关;校正临床变量后,生物标志物与生存和NRM相关,并轻微改善总生存和NRM的预测,但对D28无反应和死亡终点的增益有限。
要点
- 初始GVHD分级和胆红素水平与D28激素反应、D180总生存及D180非复发死亡均显著相关。
- 校正临床变量后,7种生物标志物组合与总生存和非复发死亡相关。
- 生物标志物组合对总生存和非复发死亡的预测有轻微改善,对D28无反应和死亡终点增益有限。
核心结论
- 在临床变量基础上加入7种血浆生物标志物组合,对D180总生存和D180非复发死亡的预测有轻微改善,但对D28激素无反应和死亡终点的增益有限。
研究设计与样本
- 前瞻性非干预研究,纳入204例急性GVHD患者,在GVHD发病时检测7种血浆生物标志物(Elafin、HGF、IL2RA、IL8、REG3、ST2、TNFRI),使用Ann Arbor/MAGIC联盟既往开发的算法进行预测。
主要发现
- 初始GVHD分级和胆红素水平与D28激素完全反应、D180总生存和D180非复发死亡均显著相关。
- 校正临床变量后,生物标志物与总生存和非复发死亡相关。
- 在临床变量基础上加入生物标志物,通过一致性指数和净重分类指数评估,对总生存和非复发死亡的预测有轻微改善。
- 决策曲线分析显示,在临床参数基础上加入生物标志物组合对D28无反应和死亡终点的获益有限。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute graft-versus-host disease (GVHD) is still the major contributor to comorbidities and mortality after allogeneic hematopoietic stem cell transplantation. The use of plasmatic biomarkers to predict early outcomes has been advocated in the past decade. The purpose of this prospective noninterventional study was to test the ability of panels including 7 biomarkers (Elafin, HGF, IL2RA, IL8, REG3, ST2, and TNFRI), to predict day 28 (D28) complete response to steroid, D180 overall survival, and D180 nonrelapse mortality (NRM). Using previous algorithms developed by the Ann Arbor/MAGIC consortium, 204 patients with acute GVHD were prospectively included and biomarkers were measured at GVHD onset for all of them. Initial GVHD grade and bilirubin level were significantly associated with all those outcomes. After adjustment on clinical variables, biomarkers were associated with survival and NRM. In addition to clinical variables, biomarkers slightly improved the prediction of overall survival and NRM (concordance and net reclassification indexes). The potential benefit of adding biomarkers panel to clinical parameters was also investigated by decision curve analyses. The benefit of adding biomarkers to clinical parameters was however marginal for the D28 nonresponse and mortality endpoints.
引用
- Robin M, Porcher R, Michonneau D, et al. Prospective external validation of biomarkers to predict acute graft-versus-host disease severity. Blood Adv. 2022. PMID: 35667096. doi:10.1182/bloodadvances.2022007477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。